Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4670402 | 0.69 | — | — | |
| SCHEMBL4452760 | 0.61 | CYP1A2 (0.33) | NPC1RAB9ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6919080 | 0.57 | ADORA3 (0.45) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30661946 | 0.56 | KDM4E (0.58) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL445070 | 0.56 | KMT2A (0.38) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL69349 | 0.56 | KMT2A (0.91) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3254014 | 0.55 | KMT2A (0.41) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL752833 | 0.55 | NISCH (0.39) | KMT2AMEN1SMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL28929770 | 0.54 | KMT2A (0.45) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1967310 | 0.54 | IDO1 (0.38) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6531511-B1 | N-methyl aspartate receptor antagonist | VERNALIS RESEARCH LIMITED (GB) | 2003-03-11 | — | — | US | claimed |
| WO-1998010653-A1 | PIPERIDINES, PYRROLIDINES AND HEXAHYDRO-1H-AZEPINES PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1998-03-19 | — | — | WO | claimed |
| WO-1997036873-A1 | PIPERIDINES, PYRROLIDINES AND HEXAHYDRO-1H-AZEPINES PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | claimed |
| US-RE46024-E1 | Thyroid hormone analogs | HOFFMANN-LA ROCHE INC. (US) | 2016-06-07 | — | — | US | disclosed |
| EP-1963313-B1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) | MADRIGAL PHARMACEUTICALS INC (US) | 2012-11-14 | — | — | EP | disclosed |
| EP-1844070-B1 | PEPTIDES WITH NEUROPEPTIDE-2 RECEPTOR (Y2R) AGONIST ACTIVITY | HOFFMANN LA ROCHE (CH) | 2011-03-02 | — | — | EP | disclosed |
| EP-2089368-B1 | DIAMINOCYCLOHEXANE AND DIAMINOCYCLOPENTANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-7807674-B2 | Thyroid hormone analogs | HOFFMANN-LA ROCHE INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7803816-B2 | MCH receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-09-28 | — | — | US | disclosed |
| EP-1919878-B1 | PYRIDAZINONE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS | HOFFMANN LA ROCHE (CH) | 2010-09-08 | — | — | EP | disclosed |
| US-7652053-B2 | Diaminocycloalkane MCH receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20040039200-A1 | Pirazino(AZA)indole derivatives | VERNALIS RESEARCH LIMITED | 2004-02-26 | — | — | US | disclosed |
| EP-1147110-B1 | PYRAZINO(AZA)INDOLE DERIVATIVES | VERNALIS RES LTD (GB) | 2003-05-07 | — | — | EP | disclosed |
| US-6531511-B1 | N-methyl aspartate receptor antagonist | VERNALIS RESEARCH LIMITED (GB) | 2003-03-11 | — | — | US | disclosed |
| EP-1147110-A1 | PYRAZINO(AZA)INDOLE DERIVATIVES | VERNALIS RESEARCH LIMITED (GB) | 2001-10-24 | — | — | EP | disclosed |
| EP-1143964-A1 | 2-ADAMANTANEMETHANAMINE COMPOUNDS FOR TREATING ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RESEARCH LIMITED (GB) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000044371-A1 | 2-ADAMANTANEMETHANAMINE COMPOUNDS FOR TREATING ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RESEARCH LIMITED (GB) | 2000-08-03 | — | — | WO | disclosed |
| WO-2000044753-A1 | PIRAZINO(AZA)INDOLE DERIVATIVES | VERNALIS RESEARCH LIMITED (GB) | 2000-08-03 | — | — | WO | disclosed |
| EP-1006112-A1 | 3-Hydroxy-2(1H)-pyridinone or 3-hydroxy-4(1H)-pyridinone derivatives useful as reactive oxygen species (ROS) scavengers | Cerebrus Pharmaceuticals Limited (GB) | 2000-06-07 | — | — | EP | disclosed |
| EP-1006108-A1 | 3-Hydroxy-2(1H)-pyridinone or 3-hydroxy-4(1H)-pyridinone derivatives useful as reactive oxygen species (ROS) scavengers | Cerebrus Pharmaceuticals Limited (GB) | 2000-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039200-A1 | Pirazino(AZA)indole derivatives | PIR, GPR119, INMT | KMT2A 1272/4885MEN1 368/4885NPC1 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.